Recent Finacing
Recent Raise
Develops RNA-targeted therapeutics that modulate lncRNA-PRC2 interactions to epigenetically upregulate genes and stabilize mRNA, advancing preclinical programs toward IND/clinic for rare genetic and neurodegenerative diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
